Introduction {#Sec1}
============

According to WHO, neglected tropical diseases (NTD) are caused by defined, often rare, pathogens, and multiple research programs aim at investigating the epidemiology, causative pathogens, and treatment of these NTDs. Conversely, this may suggest that even in resource-limited regions, prevalent pathogens such as *Staphylococcus aureus* are not 'neglected', and that the epidemiology and microbiology is rather well known or can be inferred from data from developed countries. Literature and practical experience from these regions, however, tell a different story: diagnosis and treatment of infections caused by common pathogens is hampered by a lack of microbiological facilities and a paucity of epidemiologic data^[@CR1]^.

*S*. *aureus* is a major public health threat and economic burden to health care systems worldwide causing important morbidity and high attributable mortality. Doubtlessly, *S*. *aureus* is a major pathogen also in (so-called) developing, tropical areas such as Sub-Saharan Africa, frequently causing invasive disease (for review: refs [@CR2]--[@CR4]). In developed regions, epidemiologic registries provide data on the clonal structure of the prevalent isolates^[@CR5]--[@CR8]^ yielding insight into the association of clonality, gene repertoire, and disease course. In Sub-Saharan Africa, numerous studies exist describing various *S*. *aureus* strain collections with phenotypic and/or genotypic methods^[@CR9]--[@CR20]^, yet, they have been collected from retrospective strain collections, lack accompanying clinical data, are not controlled for hospital acquisition of the isolate/disease, and have not been performed strictly comparing the genotype (as clonal complex \[CC\] attribution and putative virulence gene content). In other words, cross-sectional molecular epidemiologic studies on both methicillin-sensitive and methicillin-resistant *S*. *aureus* are largely lacking.

Hence, the goal of this study was to investigate the hypothesis that prevalent clones of clinically defined, prospectively collected, non-nosocomial, i.e. community-associated, human *S*. *aureus* isolated in a temperate climate/developed region (Germany) differ with respect to their genetic repertoire and clonal lineage when compared to clones isolated in a tropical/developing region (Sub-Saharan Africa).

Results {#Sec2}
=======

Healthy participants' and patients' characteristics are summarized in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}, respectively. The median age of asymptomatic carriers (volunteers) was 18 (0--61) years and 23 (0--89) years in the African and German study sites, respectively. Patients in Africa had a median age (range) of 3 (0--71) years, in Germany 53 (0--98) years. German patients had a higher rate of previous hospital care, or overall healthcare. German patients more frequently showed risk factors for invasive *S*. *aureus* infection (as reflected by elevated rates of Charlson comorbidity score), and in Germany a larger proportion of clinical isolates was obtained from blood cultures when compared to clinical isolates from Africa. African patients had a higher rate of skin and soft tissue infections, while deep invasive infections of the bone/joint, or respiratory tract were more frequently reported among German patients. Patients with a history of HIV infection were only found in the African group.Table 1Characteristics of healthy *Staphylococcus aureus* carriers.TotalAfrica (n = 300)Germany (n = 300)p valueMedian age in years (range)22 (0--89)18 (0--61)23 (0--89)nsMale sex, n (%)280 (47%)132 (44%)148 (49%)nsHistory of hospital admission 6 months until 4 weeks prior to sampling, n (%)14 (2%)1 (\<1%)13 (4%)\<0.01Known HIV infection, n (%)15 (3%)15 (5%)0\<0.001History of AIDS, n (%)7 (1%)7 (2%)0nsHistory of peripheral vascular disease, n (%)6 (1%)06 (2%)nsHistory of connective tissue disease, n (%)8 (1%)08 (3%)nsKnown diabetes, n (%)8 (1%)08 (3%)ns Table 2Characteristics of patients with *Staphylocococus aureus* infection from Africa and Germany.TotalAfrica (n = 300)Germany (n = 300)p valueMedian age in years (range)29 (0--98)3 (0--71)53 (0--98)\<0.001Male gender, n (%)348 (58%)160 (53%)188 (63%)nsHistory of hospital admission 6 months until 4 weeks prior to sampling, n (%)^a^157 (26%)29 (10%)128 (43%)\<0.001Healthcare contact last 4 weeks, n (%)^a^129 (22%)36 (12%)93 (31%)\<0.001Continuous residency in a nursing home before sampling, n (%)4 (\<1%)2 (\<1%)2 (\<1%)nsAntibiotic treatment in the last 4 weeks, n (%)^a^133 (22%)55 (18%)78 (26%)nsTuberculosis in the last 6 months, n (%)^a^4 (\<1%)4 (1%)0nsAntituberculous drugs in the last 4 weeks, n (%)^a^1 (\<1%)1 (\<1%)0nsRisk factors for staphylococcal diseaseHistory of intravenous drug abuse, n (%)7 (1%)07 (2%)nsIntravenous catheter in place, n (%)23 (4%)023 (8%)\<0.001Other intravascular device in place, n (%)28 (5%)028 (9%)\<0.001Non-vascular foreign body/device in place, n (%)73 (12%)3 (1%)70 (23%)\<0.001Known HIV infection, n (%)26 (4%)26 (9%)0\<0.001Charlson comorbidity score, median (range)0 (0--12)0 (0--0)1 (0--12)nsSeverity of chronic underlying disorder(s) (McCabe & Jackson classification)Rapidly fatal underlying disease, n (%)30 (5%)19 (6%)11 (4%)nsUltimately fatal disease \[\<5 years\], n (%)58 (10%)17 (6%)41 (14%)nsNon-fatal underlying disease, n (%)132 (22%)22 (7%)110 (37%)\<0.001Type of infectionBloodstream infection, n (%)79 (13%)29 (10%)50 (17%)nsNon-bacteremic infection, n (%)521 (87%)271 (90%)250 (83%)nsAcute clinical presentationSevere sepsis, n (%)38 (6%)18 (6%)20 (7%)nsSeptic shock, n (%)7 (1%)2 (\<1%)5 (2%)nsClinical site(s) of infectionBloodstream infection, n (%)79 (13%)29 (10%)50 (17%)0.02Superficial skin infection, n (%)348 (58%)191 (64%)157 (52%)nsDeep skin abscess, n (%)121 (20%)82 (27%)39 (13%)0.002Bone, n (%)22 (4%)022 (7%)\<0.001Joint, n (%)20 (3%)3 (1%)17 (6%)nsMuscle, n (%)11 (2%)4 (1%)7 (2%)nsFascia, n (%)2 (\<1%)1 (\<1%)1 (\<1%)nsRespiratory tract, n (%)25 (4%)6 (2%)19 (6%)nsHeart, n (%)5 (1%)05 (2%)nsCentral nervous system, n (%)1 (\<1%)1 (\<1%)0nsUrinary tract, n (%)7 (1%)07 (2%)nsOther, n (%)87 (15%)20 (7%)67 (22%)\<0.001^a^Data were reported as recalled by the participant. If possible, patient's healthcare files or demographic surveillance systems (i.e. Mozambique) were used to confirm these data.

1,190 isolates of the 1,200 *S*. *aureus* isolates could be assigned to 32 CC and three singleton STs. For seven isolates, the CC could not be deduced because they belonged to new MLSTs not covered by known array profiles. These isolates were either from Africa (n = 4, ST2734, ST2744, ST2370) or Germany (n = 3 ST2733, ST2678, ST2735). Three isolates (1.3%) that were not CC attributable by Iconoclust were attributed to CCs by affinity propagation (based on their MA profiles).

Figure [1](#Fig1){ref-type="fig"} displays the distribution of CCs of isolates from African and German study sites. Except for four CCs (CC80 and CC88 in Africa, CC50 and CC398 in Germany), all CCs with a number of at least six isolates were found in Africa as well as in Germany. For 17 of the 40 detected CCs and STs, significant geographic distribution differences were found. 16/22 (73%) of the most frequently encountered CCs, and the vast majority of isolates contained within these CCs (896/1168, 77%) were significantly (p \< 0.05) predominant either in Africa or in Germany. In the subgroup of clinical isolates, CCs were again significantly (p \< 0.05) predominant in Africa or Germany, respectively (with the exception of clusters of low abundance, i.e. CC6 and CC50), while of the CCs contained in the subgroup of commensal isolates, among African isolates only CC88, CC121 and CC152, and among German isolates only CC 7 and CC30 were significantly predominant. In addition, we used already published whole genome sequences of a randomly selected subset of isolates (n = 154) of this study to construct a neighbor-joining tree based on the allelic profiles of 1861 *S*. *aureus* core genome features (cgMLST, Figure [S1](#MOESM1){ref-type="media"})^[@CR21]^. On visual inspection, this analysis also shows that the majority of clusters are based on the geographical region. Clusters of isolates from infection or colonization were not detected.Figure 1Distribution of the 22 most prevalent clonal complexes (CC) in Africa and Germany among isolates from colonization and infection. CCs of low prevalence (\<6 isolates) where grouped together (others). The CCs were sorted in ascending order according to the total number of isolates in the respective CC. The proportions of clinical (red) and nasal (green) isolates in the African and German group are shown. Differences in the distribution of CCs between Africa and Germany were calculated with Fisher's exact test; \*p \< 0.05, \*\*p \< 0.001.

From the MA repertoire, all genes with a known or presumed regulator, virulence, and/or pathogenicity role were extracted, and compared between isolates from Africa and Germany (Supplementary Table [1](#MOESM1){ref-type="media"}). African isolates contain accessory gene regulators *agr* type I through type IV (with apparently some cross-hybridization between *agr*I and *agr*IV as the total number adds up to \>100%); in contrast, within German isolates the majority is of *agr*I while *agr*IV was rarely found. Overall, enterotoxin gene recognition was low; yet, *seb* hybridized positively with DNA from African isolates, while *sec*, *sed*, *sel*, and the enterotoxin gene cluster *egc* was preferentially detected in isolates from Germany. A major difference was observed with leukocidins: the genes encoding for the Panton-Valentine leukocidin (PVL) *lukF-PV* and *lukS-PV* were recognized in almost one half of African clinical strains and were virtually absent in German isolates. The *edinA* and *edinB* immune evasion genes encoding the epithelial differentiation inhibitors were more frequently found amidst African isolates as was the gene *isaB* encoding the immunodominant antigen B and the protease gene *splB*. Only fragments and not the full *map* gene encoding the extracellular adhesive protein Eap were detected among African isolates; the gene *sasG* encoding for the biofilm associated surface protein G was more frequently found among African isolates (Table [S1](#MOESM1){ref-type="media"}).

The majority of resistance genes were equally distributed among isolates from Africa and Germany. In general, methicillin resistance (*mecA*) was low in isolates from Africa (7/300 nasal \[2.3%\] vs 10/300 clinical \[3.3%\]) and Germany (2/300 nasal \[0.7%\] vs 22/300 clinical \[7.3%\]). Only *blaZ* was more frequently detected in African (560/600, 93%) vs. German isolates (400/600, 67%). Similar results were found for *ermC* (43/600 \[7%\] vs 91/600 \[15%\], p \< 0.0001) and *tetK* (15/600 \[3%\] vs 211/600 \[35%\], p \< 0.0001). *merA*, *ermA*, and *tetM* also displayed a significant difference between German and African isolates, yet, at an overall rate of target recognition of less than 10%. These findings correspond well to the phenotypic resistance profiles (Supplementary Table [2](#MOESM1){ref-type="media"}); here, striking differences in phenotypic resistance could be observed for tetracycline and trimethoprim-sulfamethoxazole with a larger proportion of resistant isolates in the African population, and clindamycin, with resistance more prevalent among German isolates.

The combined PCA/Silhouette analysis allowed to identify nine PCA clusters (labelled \#1--9, Fig. [2](#Fig2){ref-type="fig"}). Overall, the CC attribution of the isolates corresponded to these PCA clusters, i.e. the isolates confined to a PCA/silhouette cluster could be attributed to a specific CC. Clusters with preferential composition of 'African' isolates are primarily found on the left side of the PCA plot (\#2 \[CC15\], \#3 \[CC121\], \#4 \[CC152\]), whereas the clusters on the right side of the plot were preferentially of 'German' provenance (\#6 \[CC398\], and \#9 \[CC30\]). CC45 can be separated into two clusters (cluster \#7 and cluster \#8) of different geographic origin. In addition to these well-defined clusters (\#1--9), there are additional clusters of isolates (Fig. [2](#Fig2){ref-type="fig"}, dashed line) which are associated with various CCs (i.e. CC1, CC5, CC6, CC7, CC9, CC12, CC20, CC25, CC49, CC50, CC59, CC80, CC88, CC97, CC101, CC188, CC395, CC509, CC707, CC913, CC1021, CC1290) or STs (i.e. ST580, ST1093, ST2370, ST2733, ST2734, ST2735, ST2744, ST2678).Figure 2Characteristic genotypic patterns of isolate subgroups detected by DNA microarray. The cluster analysis of 1200 *S*. *aureus* isolates was performed using the principal component analysis (PCA). Each dot represents one isolate. Dots are colour coded according to the study sites in Africa (Ifakara, Tanzania (IT), Lambarene, Gabon (LG), Manhiça, Mozambique (MM)) and Germany (Münster (MW), Freiburg (FR), Homburg (HS)). Major clusters that correspond to multilocus sequence typing clonal complexes (CC) are highlighted. Genes that were significantly (p \< 0.01) associated with the respective CC are mentioned. Virulence factors that were significantly associated with ≥4 CCs are not displayed. Isolates encircled with a dashed line belong to CC1, CC5, CC6, CC7, CC9, CC12, CC20, CC25, CC49, CC50, CC59, CC80, CC88, CC97, CC101, CC188, CC395, CC509, CC707, CC913, CC1021, CC1290 or ST580, ST1093, ST2370, ST2733, ST2734, ST2735, ST2744, and ST2678.

With the Kolmogorov-Smirnoff test we identified the MA hybridization targets, which distinguished the isolates in the respective clusters \#1--9 out of all MA hybridization signals for each isolate of the collection; these genes are denoted in Fig. [2](#Fig2){ref-type="fig"}.

Discussion {#Sec3}
==========

Here we present a prospective, cross-sectional geographic comparative study on strictly community-associated *S*. *aureus* isolates recovered under controlled, identical conditions in Germany and Sub-Saharan Africa and demonstrate that the cluster repartition among African and German isolates is profoundly inhomogeneous.

Studies from Europe revealed CC45, CC5, CC15, CC30, CC8 to be the most frequently encountered clusters^[@CR5],\ [@CR6],\ [@CR8],\ [@CR22]--[@CR24]^. The overall smaller studies from Sub-Saharan Africa indicate that CC5, CC15, and CC30 are prevalent^[@CR14],\ [@CR20]^, that MSSA-CC8 has been primarily reported from North Africa (whereas MRSA-CC8 has been found in Central and South Africa), and that CC121 was more frequently reported from Sub-Saharan countries compared to Europe^[@CR2]^. Methicillin-sensitive CC80 has been more frequently reported from North Africa, and may be related to the community-associated MRSA clone ST80 prevalent in Europe^[@CR25]^. CC88 isolates are also typically methicillin-resistant; because this cluster has almost uniquely been recovered from African regions, it was attributed the acronym 'African clone'^[@CR2]^. The PVL positive clonal complex CC152 may also have originated from Africa^[@CR14]^, expanded through central Europe, then acquired the methicillin resistance^[@CR26]^. From these literature reports we conclude: first, 'typical' *S*. *aureus* clusters such as CC5, CC15, and CC30 appear to be prevalent in both Europe and Africa. Secondly, another set of 'typical' clones (such as CC80, CC88, or CC152) is reported from Africa rather than from Europe, yet, these clones do not seem to make up the bulk of isolates recovered in a non-endemic setting. Third, and probably most importantly, clear-cut studies allowing for frequency comparison between European and African clusters are lacking. The underlying mechanism of different population structures of *S*. *aureus* from Africa and Germany is unclear. The conservation of genomic patterns (e.g. gene clusters) and a subsequent clonal expansion could account for these differences. For instance, the ΦSa 2 prophage which carries *lukF-PV* and *lukS-PV* was integrated in the CC80 lineage at few occasions and subsequently clonally expanded in Africa and Europe^[@CR25]^. Factors that favor the expansion of one clone in one geographic area might be associated with the bacterium itself (e.g. competition between different clones and species). However, host and environmental factors certainly play as well an important role which should be addressed in future studies.

Our cross sectional, comparative study now proves certain CCs of isolates from Africa to be indeed significantly prevalent (CC15, CC121, CC152) or even unique (CC88, CC80) compared to Germany. On the other hand, among isolates from Germany, other CCs are either significantly prevalent (such as CC45, CC30, CC7, CC22) or unique (CC398, CC50). PCA, avoiding multiple comparisons of single target recognition, confirmed this analysis allowing clear separation of the predominant 'African' from the 'German' clusters.

Does this clonal repartition imbalance contribute to a difference in disease spectrum? In Africa, higher rates of *S*. *aureus-*related pyomyositis are reported, frequently with bone, skin, and soft tissue involvement^[@CR15],\ [@CR27]^, at times presenting with multifocal lesions^[@CR28]^. Moreover, *S*. *aureus* is particularly frequent in skin and soft tissue infections in Africa^[@CR2]^. Molecular epidemiologic studies (from US and Europe) describe CC15 (in our study, 'African'), CC30 ('German'), and CC5, CC8, CC25 (in our study, 'balanced') as associated with invasive disease^[@CR7],\ [@CR23],\ [@CR29]^, yet, they do not provide clear clues towards as to a different disease presentation as a function of predominant CCs in tropical/temperate geographic areas. Our study now provides such indication as the two CCs in our study significantly linked with clinical (as opposed to commensal) origin were the 'African' clones CC121 and CC152 (while the two CCs associated with nasal provenience were the 'German' clones CC45 and CC101).

In addition to the clonal repartition difference between Sub-Saharan Africa and Germany, does the gene repertoire composition contained in the respective, imbalanced CCs contribute to different disease presentation? In our analysis, *agr*IV was identified with an over-representation in African and *agr*I in German isolates, respectively, consistent with previous studies demonstrating *agr*IV to be prevalent in African CC121^[@CR30]^. Moreover, the previously reported difference in the positivity rate for *lukF-PV and lukS-PV* was clearly confirmed also in this study^[@CR14],\ [@CR15],\ [@CR31]^. The enterotoxin gene *seb* was also found to be predominant in African isolates, in line with results from studies performed in isolates from remote pygmy populations^[@CR31]^, particularly among isolates of CC121. Of note is the difference in recognition of *isaB* target encoding a gene only expressed *in vivo* ^[@CR32]^ inhibiting autophagic flux, thus allowing *S*. *aureus* to evade host degradation^[@CR33]^. The proteases are also considered of importance to virulence^[@CR34]^, and *splB* was significantly more often detected in African isolates (while *splE* was predominant in German isolates). Among adhesion factors, significant differences were found for *map*, the gene conferring extracellular adherence protein (Eap) expression^[@CR35]^ and for the surface protein gene *sasG*. For *map*/*eap* this difference was largely attributable to a lacking recognition of the *eap* variant in isolates of CC152 (an African isolate whose genome did also fail to hybridize with the *sdrC* target) while for *sasG* the difference was mainly attributable to CC121. These observations allow to conclude that not only the clonal attribution but also certain regulatory, pathogenicity and virulence genes are differently distributed when comparing African and German *S*. *aureus* isolates obtained from patients with community associated infection.

The MRSA prevalence in our study was very low (nasal isolates: 2%, clinical isolates: 3%) compared to many other studies from Sub-Saharan Africa (23--55%)^[@CR36]^. However, these studies should be interpreted with caution as, in contrast to our study, species of *S*. *aureus* and methicillin resistance were not confirmed. It is therefore likely that methicillin resistance is over reported in these studies.

The low rates of methicillin resistance could be also the result of strict exclusion of nosocomial, hospital-associated cases of infection. In accordance to the phenotypic data of many African studies showing a high resistance to penicillin^[@CR30]^ and tetracycline (21.8--92%)^[@CR37]^, we found a significant predominance of the beta lactamase operon and of the tetracycline resistance determinants *tetK* and *tetM* in the African isolates. Moreover, the erythromycin resistance genes *ermA* and *ermC* were more frequently found in German and African isolates, respectively (in line with a recent study^[@CR38]^). In part, these findings were also confirmed by the phenotypic resistance profile demonstrating significant differences in susceptibility to tetracycline (but not to erythromycin).

This study has a number of limitations. First, the discrepancy in population age and comorbidities between the German and African cohort potentially biases the 'true' distribution of clones and genes between isolates from the different geographic regions (although application of a multiple linear regression model for the detection rate of Panton-Valentine leucocidin genes failed to provide evidence that age acts as a confounding variable \[not shown\]). In line, the imbalance in the type of infection (as shown in Table [2](#Tab2){ref-type="table"}) between patients from Germany and Africa may also be a confounder with respect to the CC and virulence gene profile. *Ex ante* we deliberately did not attempt to match patients from Germany and Africa for age, comorbidity profiles, or type of clinical disease; instead, it was our goal to compare the patient characteristics and *S*. *aureus* isolates of a typical patient population presenting for primary medical care at German and African Medical Centers, and to avoid a potential bias incurred by imbalanced strata sizes. Secondly, the MA technique does not allow to distinguish between allelic variants not recognized by hybridization, and complete absence of alleles or genes (this issue has been investigated recently by our group comparing whole genome sequencing (WGS) and MA of exemplar isolates demonstrating that both techniques are highly but not fully reliable with respect to the gene/allele identification \[with 1.7% WGS errors and 1.8% MA errors\]^[@CR39]^). Furthermore, the amount of gene transcripts or gene products was not assayed; thus, no correlation between transcript levels and geographic isolate provenience can be inferred. Thirdly, it was not possible to quality control the reliability of clinical case ascertainment beyond the instruction of the clinical personnel on following the written detailed instruction provided together with the structured questionnaires, and attribution of clinical characteristics may therefore lack scrutiny. Fourthly, we did not engage additional study sites from Europe; therefore, our comparison is limited to German isolates. However, in contrast to MRSA, MSSA have a similar population structure across Europe^[@CR5]^. As the majority of our isolates were MSSA, results from Germany could be used as a surrogate for Europe.

In conclusion, prospectively collected, community-associated *S*. *aureus* isolates obtained from asymptomatic carriers and patients demonstrate profound and significant differences between Germany and various Sub-Saharan African regions, both with respect of clonal cluster attribution and gene repertoire, and for many genes the difference between the cohorts appears to be even more pronounced when only clinical isolates from both regions are analyzed. Thus, based on the overall clonal attribution and allele repertoire, our data provide first clues to explain the purported difference in clinical presentation and course of diseases caused by *Staphylococcus aureus*, a pathogen of major significance both in developing and developed regions.

Methods {#Sec4}
=======

Study design and participants {#Sec5}
-----------------------------

This is a cross sectional, geographical correlation study. Wherever applicable, described definitions and items on molecular epidemiology for infectious diseases study designs were applied^[@CR40]^. Between years 2010 and 2012, a total of 1200 community-associated isolates was collected in three African (Lambaréné, Gabon; Bagamoyo, Tanzania; Manhiça, Mozambique) and three German study sites (Homburg, Freiburg, Münster). Every study site collected 100 non-duplicate isolates of healthy asymptomatic carriers. Exclusion criteria were (i) hospitalization within the past four weeks, (ii) antibacterial treatment within the past four weeks, and (iii) antituberculous treatment in the past four weeks. In addition, 100 clinical non-duplicate isolates were collected from human infection at each study site. The inclusion criteria were (i) clinical suspicion of infection by the treating physician, and (ii) community-onset of disease (outpatient clinic, or \<48 h after admission). Clinical data were systematically recorded, electronically transmitted to the Freiburg study site, and checked for data consistency.

Ethical approval was obtained from the Ministry of Health and Social Welfare of Tanzania (A 81--2009), Institutional Ethics Committee of the Medical Research Unit of the International Foundation of the Albert Schweitzer Hospital (CERIL 15/09), National Committee of Bioethics for the Health System Mozambique (325/CNBS/12), Ethics Committee of the University of Münster (2009-227-b-S), Ethics Committee of Freiburg (248/09_120491) and the Ethics Committee of the Chamber of Physicians of Saarland (19/09). A written informed consent was obtained from all study subjects or their legal guardians. All experiments were performed in accordance with relevant guidelines and regulations.

Isolate collection and microbiological methods {#Sec6}
----------------------------------------------

Nasal swabs from asymptomatic carriers and appropriate specimens from infection sites were collected, and species identification performed by standard methods and confirmed at the Homburg site by MALDI-TOF (BRUKER Daltonics GmbH, Bremen, Germany). Antimicrobial susceptibility testing was performed at the various study centers using standard techniques (Clinical and Laboratory Standards Institute, M100).

All isolates were transferred into storage tubes, and shipped on dried ice to a central sample repository (Fraunhofer IBMT, Sulzbach, Germany) for long-term storage at −140 °C.

DNA microarray-based genotyping and MLST {#Sec7}
----------------------------------------

All isolates were genotyped using the IdentiBAC® DNA microarray (MA, Alere Technologies GmbH, Jena, Germany). DNA extraction (Qiagen, Hilden, Germany) and hybridization were performed according to the manufacturer's instructions. Spot signals were analyzed using ArrayMate® reader and corresponding Iconoclust® software (Alere Technologies GmbH, Jena, Germany) attributing specific multilocus sequence typing (MLST) clonal complex (CC) and sequence type (ST) designations. MLST was carried out for samples that were not assigned by the MA^[@CR41]^.

CC assignment confirmation and statistics {#Sec8}
-----------------------------------------

Correctness of the CC identification by MA was confirmed by WGS of 154 exemplars^[@CR39]^ defined by affinity propagation^[@CR42]^. Principal component analysis (PCA) was performed to represent the isolate genotype in a two-dimensional projection. Given a large set of data, PCA identifies a small number of uncorrelated variables (termed principal components) that explain the maximum amount of variance in the data. In particular, the first two variables termed PCA1 and PCA2 describe the largest and second-largest variance in the data (Fig. [2](#Fig2){ref-type="fig"}).

Statistical analysis (Kolmogorov-Smirnoff test, Hommel p-value adjustment) was used to determine genotypic differences of isolate clusters defined by PCA. All comparisons were statistically analyzed by Chi-Square adjusted for multiple testing (Hommel p-value adjustment). Chi-Square, multivariate and principal component analysis were performed with the software "R", version 3.2.0. Silhouette analysis was carried out to determine the number of different isolate clusters in the PCA, and was performed with "R", version 3.2.2, function silhouette and package "cluster" version 2.0.3 on default parameters.
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